Creatine for Women Over 40: What the Cardiac and Brain Evidence Actually Shows

In 2023, a study using magnetic resonance spectroscopy measured brain phosphocreatine levels in perimenopausal women and found them significantly lower than in age-matched premenopausal women. The same year, the American College of Sports Medicine formally recognized creatine as one of the few supplements with sufficient evidence to recommend. These two findings, arriving nearly simultaneously, are not coincidental. They point to the same biology, one that has largely been absent from conversations about women’s cardiovascular and cognitive health.

Creatine has spent decades in the gym. It belongs in the clinic.

What creatine is and why the body needs it

Creatine is a naturally occurring compound synthesized from three amino acids: arginine, glycine, and methionine. The liver and kidneys produce approximately 1-2g per day endogenously. The rest comes from diet, primarily red meat and fish. Strict vegetarians and vegans have substantially lower muscle and brain creatine stores than omnivores.

The body’s primary use of creatine is energy buffering. When a cell needs ATP rapidly, the phosphate group on phosphocreatine (PCr) is transferred to ADP, regenerating ATP within milliseconds. This is faster than glycolysis or oxidative phosphorylation. The cells that depend most heavily on this system are the ones with the highest and most variable energy demands: skeletal muscle, cardiac muscle, and neurons.

Endogenous creatine synthesis declines with age. By the time a woman is in her mid-forties, dietary intake becomes more critical to maintaining adequate PCr stores in muscle and brain.

Sex differences in creatine pharmacokinetics: why women are not small men in this context

One of the most clinically underappreciated findings in creatine research is that women start from a lower baseline. Studies using muscle biopsy and MRS have consistently shown that women have lower intramuscular creatine concentrations than men at the same level of dietary intake and training status. The gap is not trivial. Smith-Ryan and colleagues, publishing in Nutrients in 2021, summarized the sex-stratified data and found that women’s baseline muscle creatine stores run approximately 70 to 80 percent of those measured in men, even after controlling for muscle mass and dietary intake.

The mechanism behind this difference involves both synthesis and dietary supply. Creatine synthesis relies on the enzyme guanidinoacetate methyltransferase (GAMT), which produces a key creatine precursor. Some data suggests this enzymatic activity is modestly lower in women on average. More practically, women in the developed world consume less dietary creatine than men simply because meat and fish intake is lower across most dietary patterns. A woman eating a typical Western diet may be getting 0.5 to 1g of dietary creatine per day; a male counterpart eating the same diet pattern often gets closer to 1 to 2g per day from higher meat portions.

The clinical implication is counterintuitive: women may actually have more room to benefit from supplementation than men, not less. When baseline stores are lower, the percentage increase from a standard supplementation protocol is larger. Research in women shows that creatine supplementation produces measurable increases in muscle creatine concentration at doses of 3g per day, a dose that might be considered subtherapeutic in a male athlete but appears adequate for many women to reach the upper range of normal muscle saturation. 4 / Promising

A loading phase, traditionally 20g per day for five to seven days, was developed primarily in male athletic populations. It is not required to achieve full saturation in women; the same endpoint is reached with a lower daily dose over a longer period. Women who find the loading phase causes GI discomfort, which is dose-dependent, can simply start at 3g per day and allow four to six weeks for full saturation. The endpoint physiology is identical.

This matters beyond academic precision. Dosing guidance for creatine has been extrapolated almost entirely from male athlete populations for three decades. Women over forty are not the study population these protocols were designed for, and blanket application of male-derived loading protocols may explain some of the GI complaints that have historically discouraged women from continuing supplementation.

The cardiac energy system: why the heart runs on phosphocreatine

The heart does not store fuel the way skeletal muscle does. It is continuously active and must regenerate ATP without pause, a demand oxidative metabolism handles under normal conditions. But during high-demand states, spikes in heart rate, sudden exertion, arrhythmia, or periods of reduced coronary perfusion, the phosphocreatine buffer provides a crucial reserve.

In healthy hearts, the PCr-to-ATP ratio is approximately 1.5 to 2.0. In patients with heart failure, this ratio falls measurably. Multiple MRS studies have documented cardiac PCr depletion in heart failure patients, and the degree of depletion correlates with functional severity. This is not a peripheral effect: it represents a documented metabolic deficiency in the failing myocardium.

Small randomized trials have investigated creatine supplementation in heart failure patients, with some showing improvement in exercise capacity and skeletal muscle strength. 4 / Promising

Whether creatine supplementation produces measurable cardiac PCr benefit in women without heart failure, whose cardiac PCr may be partially reduced but not depleted, remains unstudied at scale. The mechanism is coherent; the evidence in the non-heart-failure population is not yet available from large trials.

Sarcopenia: the cardiovascular risk factor that gets missed

This is where the cardiac evidence for creatine in healthy women over 40 is strongest, though indirect.

Sarcopenia, the age-related loss of skeletal muscle mass and function, is an independent cardiovascular risk factor. Low muscle mass predicts cardiovascular events, all-cause mortality, and reduced survival after cardiac events, across multiple large prospective cohort studies. The mechanisms are several: sarcopenic individuals have lower insulin sensitivity, higher inflammatory burden, worse exercise tolerance, and reduced capacity for the metabolic adaptations that protect the heart.

Creatine monohydrate combined with resistance training maintains muscle mass and function more effectively than resistance training alone. This is among the most replicated findings in supplement science, across more than 500 randomized controlled trials. 5 / Solid

For a woman in her mid-forties who is losing muscle at the accelerated rate perimenopause brings, creatine is not a performance supplement. It is a sarcopenia mitigation strategy with cardiovascular implications.

The brain connection: estrogen, phosphocreatine, and perimenopause

The brain is an energy-intensive organ. While neurons rely primarily on glucose, phosphocreatine serves as a critical buffer against the brief ATP deficits that occur during intense cognitive activity. This system is supported by creatine transporter proteins whose expression is partially regulated by estrogen.

As estrogen declines during perimenopause, several brain energy changes occur simultaneously. Cerebral glucose metabolism decreases in estrogen-sensitive regions. Brain creatine transport efficiency may decline. The net effect is a brain that is working harder to maintain the same energy balance it managed effortlessly at thirty-five.

MRS studies have documented reduced brain phosphocreatine in perimenopausal women relative to premenopausal controls. 3 / Early

Randomized trials of creatine supplementation and cognitive function have produced meaningful results. A protocol of 20g per day for five days improved cognitive performance in sleep-deprived adults. Six weeks of supplementation at 5g per day improved processing speed, memory, and executive function in trials examining stress and cognitive load. 4 / Promising

The specific data in perimenopausal women is sparser. A small but well-designed RCT found that creatine supplementation improved measures of cognitive function in postmenopausal women compared to placebo. The sample sizes are not large enough to make definitive claims. The signal is consistent with the mechanism, which makes it worth tracking as the research matures.

What the cognitive RCTs actually show: a closer read

Because “creatine helps the brain” has become a popular claim in wellness spaces, it is worth being precise about what the controlled trial evidence actually demonstrates, and where the uncertainty remains.

McMorris and colleagues published work examining creatine supplementation and cognitive performance in older adults, finding that creatine improved working memory scores relative to placebo, with effect sizes in the range that would be considered clinically modest but measurable. The population was adults over sixty, not specifically perimenopausal women, but the mechanism is the same: replenishing brain PCr stores improves the buffer available during cognitively demanding tasks. 4 / Promising

Separate work on sleep deprivation and creatine provides a useful model. When the brain is under energy stress, whether from sleep loss, estrogen withdrawal, or metabolic dysregulation, the PCr buffer becomes more important, not less. Rae and colleagues demonstrated that creatine supplementation improved performance on tasks requiring rapid information processing in healthy young adults, with the largest benefits seen under conditions of high cognitive demand. The implication for perimenopausal women, whose brain energy metabolism is already under estrogen-withdrawal stress, is that the cognitive benefit signal may be strongest precisely in this group. This is a hypothesis grounded in mechanism, not a proven clinical finding. 3 / Early

What the evidence does not yet show is prevention or reversal of clinically significant cognitive decline. The studies are of short duration, small sample size, and do not target women with diagnosed mild cognitive impairment. The brain fog that accompanies perimenopause, which can include word-finding difficulty, reduced processing speed, and working memory lapses, is real and neurobiologically grounded. Whether creatine supplementation produces meaningful subjective improvement in this symptom for most women is a question the available trials cannot yet answer definitively.

What a clinician can say honestly: the mechanism is coherent, the safety profile at standard doses is excellent, and the early signals are in a consistent direction. For a woman already considering creatine for muscle and metabolic reasons, the potential cognitive benefit is a reasonable secondary consideration. It should not be framed as a dementia prevention strategy or a substitute for addressing cardiovascular risk factors, which are among the strongest modifiable determinants of long-term cognitive health.

Safety: the creatinine clarification

Creatine is among the most extensively studied supplements in human clinical research. Its safety profile at 3-5g per day is well characterized.

Water retention: An initial increase of approximately 1-3 pounds represents intracellular hydration of muscle cells, not fat accumulation. This stabilizes within the first two to four weeks. 5 / Solid

Kidney function: No evidence of harm in individuals with normal renal function across decades of trials and over 500 RCTs. The critical distinction: creatine supplementation raises serum creatinine slightly, because creatinine is the metabolic byproduct of creatine. This rise does not indicate kidney injury. It is a predictable metabolic effect that clinicians should know to interpret correctly. Women with existing kidney disease should not supplement without physician supervision.

Drug interactions: None established at standard doses in the published literature.

GI tolerance: A small percentage of people experience GI discomfort. This is more common with higher doses and resolves at lower doses or with food.

Practical approach: 3-5g of creatine monohydrate per day, taken consistently, with or without food. No loading phase required, though a loading phase accelerates the time to full muscle saturation. Generic creatine monohydrate from a reputable manufacturer performs identically to premium branded products.

Kidney biomarkers and how to interpret labs correctly

The kidney safety question deserves a section of its own because the lab interpretation issue has real consequences in clinical practice. Women who start creatine supplementation and then get routine bloodwork may see their serum creatinine rise and, understandably, become concerned. A clinician who is not aware of the supplementation may escalate unnecessarily: more labs, a nephrology referral, or a recommendation to stop an otherwise beneficial supplement.

Here is the biochemistry. Creatine is converted to creatinine in muscle at a rate proportional to total creatine content. When you supplement creatine, you increase the total body creatine pool. More creatine turns over to creatinine daily, and more creatinine appears in the blood and urine. This is a metabolic byproduct of normal creatine cycling, not a sign of reduced kidney clearance. The kidneys are not damaged; they are simply excreting more of a normal waste product. 5 / Solid

The typical magnitude of this rise in healthy women is modest: serum creatinine may increase from a baseline of 0.7 to 0.9 mg/dL, or similarly proportional moves depending on baseline. GFR estimates calculated from creatinine (such as CKD-EPI) will decrease correspondingly, because the formula interprets higher creatinine as worse kidney function. This is a formula artifact, not a clinical reality.

Cystatin C, an alternative kidney function marker not derived from creatine metabolism, is unaffected by creatine supplementation and provides a cleaner read on actual GFR in someone supplementing creatine. In any woman whose creatinine rises after starting creatine and for whom kidney function is a genuine clinical question, cystatin C-based GFR estimation is the more informative test.

The practical steps: inform the ordering clinician before starting creatine so the baseline creatinine is documented. Get a creatinine at baseline and at six to eight weeks. A rise of 0.1 to 0.2 mg/dL in the context of new creatine supplementation, with no other symptoms, no change in urine output, no edema, and no other metabolic changes, is expected and not grounds for stopping supplementation. Women with known CKD at any stage should discuss supplementation specifically with their nephrologist, because the margin for misinterpreting rising creatinine is lower when baseline kidney function is already impaired.

What this means for clinical practice

Creatine does not fit neatly into either the supplement category or the pharmaceutical category. It is a dietary constituent that most women over 40 are obtaining in insufficient amounts from food, especially as red meat and fish consumption declines with age, and whose endogenous synthesis also declines.

The evidence supports discussing creatine with a clinician for women who:

• Are experiencing muscle loss or reduced strength despite activity
• Have a family history that raises cardiovascular concern in the context of sarcopenia risk
• Are in perimenopause and experiencing cognitive slowing they want to address with evidence-based options
• Already resistance train and want to preserve the muscle that training builds

The conversation is worth having. The evidence behind it is real, even where it is early.

Related reading

For the cognitive changes perimenopause brings and when they require cardiac evaluation: Perimenopause Brain Fog and the Cardiac Signal.

For why resistance training is the cardiovascular foundation that strength builds on: Why Strength Training Belongs in Every Woman’s Heart Plan.

For the supplement with the closest evidence profile in terms of cardiac mechanism: Magnesium for Perimenopause: Which Form and Why.